Decrease of cellular cAMP levels in response to a concentration range of melatonin treatments. by Cathryn S. D. Maienza (20629929)

Penalty conversions yield large practical decreases, but robustness and generalizability of result are limited by data quality and sample selection. by Ryan J. Treves (13527735)

Juvenile demyelination leads to a substantial decrease in potassium currents in PV interneurons of the PFC. by Sara Hijazi (21656615)

Subjects:

Algorithm operation steps. by Junyan Wang (4738518)

Subjects:

Trends of incident opioid users, L-TOT users, and L-TOT discontinuers between 2009 and 2013. by Qian Cai (112039)

Subjects:

The yearly numerator, denominator and rate of incident opioid users, L-TOT users and L-TOT discontinuers from 2009 to 2019. by Qian Cai (112039)

Subjects:

Incidence rate ratios of negative binominal regression models for yearly rates of incident opioid users, L-TOT users and L-TOT discontinuers during 2009–2013 and 2015–2019. by Qian Cai (112039)

Subjects:

Demographic, comorbidity, concurrent drug, and opioid characteristics, among L-TOT users and L-TOT discontinuers between 2009–2019. by Qian Cai (112039)

Subjects:

Demonstration of test steps. by Jin Zhu (164147)

Subjects:

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

Graphs showing the temporal effects of temperature at the four different positions during a drilling sequence with guide drilling in two steps and final widening drilling (MIPS) an... by Marsel Ganeyev (21453399)

Subjects:

Increase in physical activity (100 step, 500 steps or 1000 steps) after the challenge according to decrease in screen time < or ≥60 minutes. by Annaëlle Le Steunf (19838110)

Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)). by Mobina Faqani (22783963)

“…<p>Summary of the effect of MPDD on SDLP across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease)).…”

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”